MedTrace Logo

Predictive Proteomic Factors of the Response to Concomitant Radiochemotherapy in Esophageal Cancer

NCT00911092 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2012-01-02

No results posted yet for this study

Summary

The scope of the trial is to predict the early complete clinical response to exclusive concomitant radiochemotherapy in esophageal cancer by the study of the pre- and per- therapeutic proteomic profile.

Conditions

  • Esophageal Cancer

Interventions

PROCEDURE

Blood sampling

Before any study treatment, 14 days after radiotherapy, 15 weeks after radiotherapy

RADIATION

Radiation

Week 1 to week 5-6 1.8-2 Gys/fraction, 5 days a week for a total of 5 to 6 weeks

DRUG

Chemotherapy (Fluorouracil and Cisplatin)

At weeks 1, 5, 8 and 11 * Day 1 to day 4: Fluorouracil 1 gr/m²/day * Day 1 or 2: Cisplatin 75 mg/m²

Sponsors & Collaborators

  • Centre Oscar Lambret

    lead OTHER

Principal Investigators

  • ADENIS Antoine, MD, PhD · Centre Oscar Lambret

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2011-09-30
Completion
2011-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00911092 on ClinicalTrials.gov